Jordan Karlitz
Concepts (147)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Colorectal Neoplasms | 24 | 2025 | 751 | 6.390 |
Why?
| Early Detection of Cancer | 14 | 2025 | 369 | 3.260 |
Why?
| Colorectal Neoplasms, Hereditary Nonpolyposis | 5 | 2021 | 33 | 2.950 |
Why?
| Adenocarcinoma | 7 | 2024 | 894 | 2.390 |
Why?
| Carcinoid Tumor | 3 | 2022 | 24 | 2.230 |
Why?
| Colonoscopy | 8 | 2021 | 235 | 1.290 |
Why?
| Colonic Neoplasms | 5 | 2022 | 243 | 1.200 |
Why?
| Telemedicine | 3 | 2021 | 786 | 1.160 |
Why?
| Mass Screening | 6 | 2022 | 1146 | 0.880 |
Why?
| Genetic Testing | 2 | 2018 | 428 | 0.870 |
Why?
| Appendiceal Neoplasms | 1 | 2022 | 26 | 0.800 |
Why?
| Incidence | 9 | 2024 | 2638 | 0.790 |
Why?
| SEER Program | 7 | 2022 | 206 | 0.780 |
Why?
| Adenoma | 2 | 2021 | 212 | 0.730 |
Why?
| Immunohistochemistry | 5 | 2021 | 1668 | 0.730 |
Why?
| Disease Transmission, Infectious | 1 | 2020 | 55 | 0.670 |
Why?
| United States | 17 | 2025 | 13840 | 0.630 |
Why?
| Microsatellite Instability | 2 | 2018 | 37 | 0.620 |
Why?
| Colonic Polyps | 1 | 2020 | 87 | 0.610 |
Why?
| Health Status Disparities | 2 | 2020 | 255 | 0.600 |
Why?
| Betacoronavirus | 1 | 2020 | 247 | 0.570 |
Why?
| Practice Patterns, Physicians' | 2 | 2018 | 1262 | 0.560 |
Why?
| Age of Onset | 5 | 2022 | 495 | 0.520 |
Why?
| Colectomy | 2 | 2015 | 94 | 0.510 |
Why?
| Pneumonia, Viral | 1 | 2020 | 337 | 0.490 |
Why?
| Family | 1 | 2020 | 649 | 0.490 |
Why?
| Coronavirus Infections | 1 | 2020 | 333 | 0.490 |
Why?
| Humans | 39 | 2025 | 128495 | 0.460 |
Why?
| Rectal Neoplasms | 3 | 2021 | 136 | 0.440 |
Why?
| Age Factors | 6 | 2022 | 3122 | 0.430 |
Why?
| Colorectal Surgery | 1 | 2013 | 22 | 0.430 |
Why?
| Pandemics | 1 | 2020 | 1477 | 0.380 |
Why?
| Immunocompetence | 1 | 2010 | 43 | 0.350 |
Why?
| Middle Aged | 16 | 2025 | 30921 | 0.350 |
Why?
| Germ-Line Mutation | 2 | 2021 | 138 | 0.340 |
Why?
| Adult | 17 | 2022 | 35299 | 0.340 |
Why?
| Herpesvirus 4, Human | 1 | 2010 | 152 | 0.330 |
Why?
| Risk Assessment | 4 | 2022 | 3232 | 0.310 |
Why?
| Louisiana | 2 | 2021 | 27 | 0.310 |
Why?
| Colitis | 1 | 2010 | 240 | 0.290 |
Why?
| Male | 16 | 2025 | 63043 | 0.270 |
Why?
| Carcinoma | 2 | 2021 | 215 | 0.270 |
Why?
| Uterine Diseases | 1 | 2006 | 15 | 0.260 |
Why?
| Colonic Diseases | 1 | 2006 | 32 | 0.260 |
Why?
| Proto-Oncogene Proteins p21(ras) | 2 | 2017 | 259 | 0.260 |
Why?
| Inflammatory Bowel Diseases | 1 | 2010 | 320 | 0.260 |
Why?
| Endometriosis | 1 | 2006 | 48 | 0.250 |
Why?
| Risk Factors | 6 | 2022 | 9737 | 0.250 |
Why?
| Health Services Accessibility | 2 | 2025 | 901 | 0.240 |
Why?
| Occult Blood | 2 | 2021 | 30 | 0.240 |
Why?
| Female | 16 | 2025 | 68266 | 0.230 |
Why?
| Neoplasm Staging | 4 | 2022 | 1292 | 0.230 |
Why?
| Feces | 2 | 2025 | 442 | 0.230 |
Why?
| Patient Compliance | 3 | 2025 | 560 | 0.210 |
Why?
| Rural Population | 2 | 2018 | 517 | 0.200 |
Why?
| Appendectomy | 1 | 2022 | 76 | 0.190 |
Why?
| Clinical Competence | 1 | 2009 | 1009 | 0.190 |
Why?
| Cost-Benefit Analysis | 2 | 2021 | 569 | 0.190 |
Why?
| MutL Protein Homolog 1 | 1 | 2021 | 12 | 0.190 |
Why?
| Adenomatous Polyposis Coli Protein | 1 | 2021 | 20 | 0.190 |
Why?
| DNA Mismatch Repair | 1 | 2021 | 47 | 0.180 |
Why?
| Cross-Sectional Studies | 3 | 2021 | 5045 | 0.180 |
Why?
| Forecasting | 2 | 2020 | 356 | 0.180 |
Why?
| Mutation, Missense | 1 | 2021 | 315 | 0.160 |
Why?
| Diagnosis, Differential | 2 | 2016 | 1412 | 0.160 |
Why?
| Pathologists | 1 | 2018 | 17 | 0.150 |
Why?
| Gastroenterologists | 1 | 2018 | 18 | 0.150 |
Why?
| Insurance, Health | 1 | 2020 | 267 | 0.150 |
Why?
| Lymph Nodes | 2 | 2014 | 466 | 0.150 |
Why?
| Congresses as Topic | 1 | 2019 | 211 | 0.140 |
Why?
| Medicaid | 1 | 2021 | 433 | 0.140 |
Why?
| Organizational Objectives | 1 | 2017 | 71 | 0.140 |
Why?
| Feasibility Studies | 1 | 2021 | 863 | 0.140 |
Why?
| Medicare | 2 | 2021 | 719 | 0.140 |
Why?
| Physician's Role | 1 | 2018 | 203 | 0.130 |
Why?
| DNA Mutational Analysis | 1 | 2017 | 385 | 0.130 |
Why?
| Retrospective Studies | 4 | 2021 | 14471 | 0.130 |
Why?
| Neoplastic Syndromes, Hereditary | 1 | 2016 | 38 | 0.120 |
Why?
| Health Care Costs | 1 | 2018 | 366 | 0.120 |
Why?
| Physician-Patient Relations | 1 | 2020 | 530 | 0.120 |
Why?
| Preoperative Period | 1 | 2015 | 113 | 0.110 |
Why?
| Neoplasms, Multiple Primary | 1 | 2015 | 54 | 0.110 |
Why?
| Preoperative Care | 1 | 2016 | 336 | 0.110 |
Why?
| Neoplasms, Second Primary | 1 | 2015 | 106 | 0.110 |
Why?
| Societies, Medical | 1 | 2017 | 744 | 0.110 |
Why?
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2021 | 1562 | 0.100 |
Why?
| Urban Population | 1 | 2015 | 441 | 0.100 |
Why?
| Endoscopy, Gastrointestinal | 2 | 2010 | 217 | 0.090 |
Why?
| Jejunal Diseases | 1 | 2010 | 7 | 0.090 |
Why?
| Choristoma | 1 | 2010 | 21 | 0.090 |
Why?
| Quality Improvement | 1 | 2018 | 1097 | 0.090 |
Why?
| Veterans | 1 | 2021 | 1397 | 0.080 |
Why?
| Young Adult | 3 | 2020 | 12349 | 0.080 |
Why?
| Ribavirin | 1 | 2010 | 91 | 0.080 |
Why?
| Abdominal Pain | 2 | 2010 | 144 | 0.080 |
Why?
| Interferon-alpha | 1 | 2010 | 193 | 0.080 |
Why?
| Pancreas | 1 | 2010 | 306 | 0.070 |
Why?
| Prevalence | 1 | 2015 | 2553 | 0.070 |
Why?
| Hepatitis C | 1 | 2010 | 237 | 0.070 |
Why?
| Aged | 6 | 2025 | 21974 | 0.070 |
Why?
| Brain Neoplasms | 1 | 2016 | 1172 | 0.070 |
Why?
| Registries | 1 | 2014 | 1883 | 0.070 |
Why?
| Proportional Hazards Models | 2 | 2021 | 1200 | 0.070 |
Why?
| Surveys and Questionnaires | 1 | 2018 | 5371 | 0.060 |
Why?
| Biopsy, Needle | 1 | 2006 | 187 | 0.060 |
Why?
| Ovariectomy | 1 | 2006 | 136 | 0.060 |
Why?
| Hysterectomy | 1 | 2006 | 118 | 0.060 |
Why?
| Vasculitis | 1 | 2005 | 59 | 0.060 |
Why?
| Polyethylene Glycols | 1 | 2010 | 600 | 0.060 |
Why?
| Brain Diseases | 1 | 2005 | 137 | 0.060 |
Why?
| Time Factors | 1 | 2015 | 6505 | 0.060 |
Why?
| Antiviral Agents | 1 | 2010 | 711 | 0.060 |
Why?
| California | 1 | 2025 | 398 | 0.050 |
Why?
| Language | 1 | 2025 | 280 | 0.050 |
Why?
| Celiac Disease | 1 | 2005 | 286 | 0.050 |
Why?
| Europe | 1 | 2022 | 360 | 0.050 |
Why?
| North America | 1 | 2022 | 290 | 0.050 |
Why?
| Chemotherapy, Adjuvant | 1 | 2021 | 381 | 0.040 |
Why?
| Colonography, Computed Tomographic | 1 | 2018 | 6 | 0.040 |
Why?
| Disease Progression | 1 | 2006 | 2604 | 0.040 |
Why?
| Follow-Up Studies | 1 | 2006 | 4874 | 0.030 |
Why?
| Mutation | 2 | 2017 | 3696 | 0.030 |
Why?
| Aged, 80 and over | 2 | 2017 | 7057 | 0.030 |
Why?
| Carcinoembryonic Antigen | 1 | 2014 | 41 | 0.030 |
Why?
| Survival Analysis | 1 | 2017 | 1265 | 0.030 |
Why?
| Genetic Predisposition to Disease | 1 | 2022 | 2269 | 0.030 |
Why?
| Sex Factors | 1 | 2018 | 1951 | 0.030 |
Why?
| Prognosis | 1 | 2021 | 3780 | 0.030 |
Why?
| Treatment Outcome | 1 | 2006 | 10162 | 0.020 |
Why?
| Urban Health | 1 | 2010 | 79 | 0.020 |
Why?
| Drug Therapy, Combination | 1 | 2010 | 1016 | 0.020 |
Why?
| Recombinant Proteins | 1 | 2010 | 1291 | 0.020 |
Why?
| Infant, Newborn | 1 | 2017 | 5740 | 0.020 |
Why?
| CD2 Antigens | 1 | 2005 | 5 | 0.020 |
Why?
| Gene Rearrangement, gamma-Chain T-Cell Antigen Receptor | 1 | 2005 | 8 | 0.020 |
Why?
| Complement C4b | 1 | 2005 | 9 | 0.020 |
Why?
| Complement C1q | 1 | 2005 | 37 | 0.020 |
Why?
| CD3 Complex | 1 | 2005 | 101 | 0.020 |
Why?
| Fatal Outcome | 1 | 2005 | 301 | 0.010 |
Why?
| Complement C3 | 1 | 2005 | 198 | 0.010 |
Why?
| Cohort Studies | 1 | 2014 | 5402 | 0.010 |
Why?
| Infant | 1 | 2017 | 9001 | 0.010 |
Why?
| Child, Preschool | 1 | 2017 | 10487 | 0.010 |
Why?
| Polymerase Chain Reaction | 1 | 2005 | 1027 | 0.010 |
Why?
| Peptide Fragments | 1 | 2005 | 688 | 0.010 |
Why?
| Adolescent | 1 | 2017 | 20304 | 0.010 |
Why?
| Child | 1 | 2017 | 20805 | 0.010 |
Why?
|
|
Karlitz's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|